Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

MOMENTUM 3 Continued Access Protocol

NCT02892955 · View on ClinicalTrials.gov ↗

Study Summary

The objective of the study is to continue to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the the MOMENTUM 3 IDE Study.

Interventions

  • DEVICE HeartMate 3 LVAS

Study Locations (20)

California

  • Cedars Sinai Medical Center — Beverly Hills
  • University of California, San Diego — La Jolla
  • Sutter Memorial Hospital — Sacramento
  • Sharp Memorial Hospital — San Diego
  • California Pacific Medical Center — San Francisco
  • Stanford University — Stanford

Florida

  • Shands Hospital @ University of Florida — Gainesville
  • Florida Hospital — Orlando
  • Tampa General Hospital — Tampa

Illinois

  • Northwestern Memorial Hospital — Chicago
  • University of Chicago Medical Center — Chicago
  • Advocate Christ Medical Center — Oak Lawn

Georgia

  • Piedmont Heart Institute — Atlanta
  • Emory University Hospital — Atlanta

Indiana

  • IU Health/Methodist Hospital — Indianapolis
  • St. Vincent Hospital — Indianapolis

Arkansas

  • Baptist Health Medical Center - Little Rock — Little Rock

Colorado

  • University of Colorado Hospital — Aurora

Connecticut

  • Yale New Haven Hospital — New Haven

Trial Details

FieldValue
Enrollment Target 1,685 participants
Start Date 2016-08
Est. Completion 2021-03
Phase NA

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02892955

The ClinicalTrials.gov registry entry for NCT02892955 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,685 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Advanced Refractory Left Ventricular Heart Failure appearing as the primary indexed condition, and to 1 intervention — of which HeartMate 3 LVAS is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02892955 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02892955 about?

NCT02892955 is a clinical study titled "MOMENTUM 3 Continued Access Protocol". The objective of the study is to continue to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the the MOMENTUM 3 IDE Study.

What is the current status of trial NCT02892955?

This trial is currently completed. It is a NA study. The enrollment target is 1,685 participants. The study started on 2016-08. Estimated completion is 2021-03.

What conditions does trial NCT02892955 study?

This clinical trial studies the following conditions: Advanced Refractory Left Ventricular Heart Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02892955?

The interventions under investigation include: HeartMate 3 LVAS (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02892955?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02892955 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial